Live tape
Top 8, mentions 7d30,017NVDA14,564 mentions▲ +0.04ANT4,160 mentions▲ +0.06GOOGL2,936 mentions▲ +0.04SPY2,248 mentions▲ +0.05QQQ1,804 mentions▲ +0.04SPCX1,748 mentions▲ +0.08AMD1,367 mentions▲ +0.06AAPL1,190 mentions▲ +0.04

Equity · Healthcare

IMRX

NASDAQ

Immuneering (IMRX)

4.63 USD −7.40% vs prior close
Immuneering Corporation price graph

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.

Market cap
299.5M USD
EPS, diluted, year to Dec 2025
−1.27 USD
52-week range
3 USD – 13 USD
Avg volume
255.9K

as of Jul 17, 2026

Have Immuneering (IMRX) insiders bought or sold shares recently?

In the 90 days to 22 Nov 2026, Immuneering insiders reported 1 open-market purchase and no sales (SEC Form 4).

Form 4, 90 days to 22 Nov 2026, newest reported trade 13 Nov 2026

1buys
0sells
$90Knet bought
0other filings
Have Immuneering (IMRX) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
13 Nov 2026Gengos AndrewChief Financial OfficerBuy25,00090K USD

Which funds hold Immuneering (IMRX)?

7 of the 45 institutional funds we track reported a Immuneering position for the quarter ended 30 Sep 2026 — a combined 4.7M USD; the latest of those filings landed 16 Nov 2026.

Form 13F

Which funds hold Immuneering (IMRX)?
FundPositionSharesValueShares q/q
Marshall WaceHeld (±25%)734,3663.0M USD+0.3%
Fisher Asset ManagementAdded115,954475K USD+31.3%
Citadel AdvisorsTrimmed89,895368K USD−76.7%
Two Sigma InvestmentsTrimmed68,545281K USD−76.2%
D. E. Shaw & Co.Trimmed67,920278K USD−66.7%
Millennium ManagementTrimmed43,712179K USD−86.8%
AQR Capital ManagementNew position23,46096K USD

What has been filed or recorded for Immuneering (IMRX)?

The filings we hold for Immuneering, newest first: 9 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 30 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Immuneering (IMRX)?
And
30 Oct 2026Fails to deliverShares failed to deliver5,041 shares20K USD notional · 0.008% of shares out
22 Oct 2026Fails to deliverShares failed to deliver2,188 shares8K USD notional · 0.003% of shares out
21 Oct 2026Fails to deliverShares failed to deliver1,748 shares7K USD notional · 0.003% of shares out
20 Oct 2026Fails to deliverShares failed to deliver10 shares37 USD notional · <0.001% of shares out
16 Oct 2026Fails to deliverShares failed to deliver14,833 shares54K USD notional · 0.023% of shares out
15 Oct 2026Fails to deliverShares failed to deliver6,429 shares22K USD notional · 0.010% of shares out
09 Oct 2026Fails to deliverShares failed to deliver248,059 shares928K USD notional · 0.383% of shares out
08 Oct 2026Fails to deliverShares failed to deliver818 shares3K USD notional · 0.001% of shares out
07 Oct 2026Fails to deliverShares failed to deliver36,955 shares142K USD notional · 0.057% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −0.37 USD
30 Sep 2026FinancialsTotal assets182.6M USDat period end
30 Sep 2026FinancialsTotal equity168.7M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.27 USD
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.21 USD
31 Dec 2025Annual reportFY 2025 reportedEPS −1.27 USD
31 Dec 2025FinancialsNet income−56.0M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−1.27 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.38 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.40 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.42 USD
31 Dec 2024Annual reportFY 2024 reportedEPS −2.04 USD

What do people ask about Immuneering (IMRX)?

From live data
What is Immuneering’s market cap?299.5M

Immuneering is worth 299.5M USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.

Have Immuneering insiders bought or sold shares recently?1 purchase

In the 90 days to 22 Nov 2026, Immuneering insiders reported 1 open-market purchase and no sales (SEC Form 4). See Insiders

Which funds own Immuneering?7 of 45

7 of the 45 funds we track reported a Immuneering position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Marshall Wace, Fisher Asset Management and Citadel Advisors. See Funds

When did Immuneering last report earnings?−0.37

Immuneering last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.37 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings
  9. SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words